Lonza Completes Expansion of Conjugation Facility in Visp
Expansion adds development and manufacturing capacity for pre-clinical, clinical and commercial supply of bioconjugates and antibody-drug conjugates
Lonza announced that a planned expansion of its bioconjugation facility in Visp (CH) is complete.
Visp, Switzerland
Lonza AG
The expansion includes two manufacturing suites and supporting infrastructure. It will support an extended customer portfolio, including companies entering clinical development. The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates.
The new suites complement Lonza’s recent investments and asset extensions in Visp (CH) in mammalian capacity, microbial development, drug product development and manufacturing, and HPAPI payload-linker manufacturing capacity. These continued investments into the Visp (CH) site provide a flexible solution for customers of all sizes at a single location. They are designed to help customers navigate the risks of a complex bioconjugation supply chain. In addition to the two new manufacturing suites, the expansion also includes an increase in process and analytical development and quality control capacity to support future portfolio growth.
Stefan Egli, Vice President, Head of Bioconjugates, Lonza, commented: “The opening of the new bioconjugate manufacturing suites in Visp (CH) reflects our dedication to continuously improving our offering and expertise in line with anticipated market and customer needs. Combined with our offerings across drug substance and drug product manufacturing in small molecules and biologics, our bioconjugation services can support projects from early phase through to late-stage and commercial programs.”
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.
Last viewed contents
Right under your nose: A more convenient way to diagnose Alzheimer's disease - Certain proteins in nasal discharge can indicate the onset and progression of Alzheimer's, providing an avenue for early detection
Novartis Phase III study shows ACZ885 helped substantially reduce steroid use in 45% of patients with serious form of childhood arthritis - Chronic steroid use to treat the symptoms of systemic juvenile idiopathic arthritis (SJIA) can contribute to slowed growth and delayed puberty
Novel discovery in dendritic cell signalling pathways pave the way for new therapeutic targets
Galapagos initiates Proof-of-Mechanism clinical study for candidate cachexia drug GLPG0492
A novel method to precisely deliver therapeutics inside the body - Ultrasound-controlled nanomaterials can provide on-demand, high precision delivery of proteins into human cells
Agilent Technologies Opens Global Manufacturing Facility for Life Sciences Instruments
GE Healthcare acquires bioprocessing start-up - Obtaining nanofiber-based platform purification technology for biopharmaceutical production
Analyze proteins and protein interactions with hitherto unseen performance - Life-science startup Actome announces release of first commercial products
Bayer CropScience accelerates expansion of biotech and seed business with investments of around EUR 3.5 billion through 2018
Falling Walls announces Science Breakthrough of the Year 2023 laureates - “These outstanding breakthroughs will change the face of the world and impressively prove what ingenuity, curiosity and courage can achieve”
